ABAXIS Announces Appointment of Brenton Hanlon to Vice President of North American Medical Sales and Marketing
10 8월 2009 - 8:30PM
PR Newswire (US)
UNION CITY, Calif., Aug. 10 /PRNewswire-FirstCall/ -- Abaxis, Inc.
(NASDAQ:ABAX), a medical products company manufacturing
point-of-care blood analysis instruments for both the medical and
veterinary markets, announced today the appointment of Brenton
Hanlon to the position of vice president of North American medical
sales and marketing, effective immediately. Mr. Hanlon, a member of
the Abaxis Board of Directors since 1996, has resigned his position
on the Board to assume this management/operational position within
the Company. Mr. Hanlon has been a medical diagnostic professional
and corporate executive with more than 35 years of experience. He
has a strong background in general management, marketing, sales,
quality control and R&D experience with in-vitro diagnostics
and medical companies. From 2001 to August 2009, Mr. Hanlon served
as president and chief executive officer of Hitachi Chemical
Diagnostics, a manufacturer of in vitro allergy diagnostic
products. Concurrently, from December 1996 until August 2009, Mr.
Hanlon has served as president and chief operating officer of
Tri-Continent Scientific, a subsidiary of Hitachi Chemical,
specializing in liquid-handling products and instrument components
for the medical diagnostics and biotechnology industries. From 1989
to December 1996, Mr. Hanlon was vice president and general manager
of Tri-Continent Scientific. Mr. Hanlon serves on the board of
directors of two privately-held companies. Clint Severson, chairman
and chief executive officer of Abaxis commented, "We are pleased to
have an industry professional with the experience and skill set of
Brenton Hanlon as our new vice president of North American Medical
Sales and Marketing. Brenton has a long history of success in the
industry and we believe he is uniquely qualified to lead Abaxis'
sales and marketing initiatives into the future. His diagnostic
industry expertise will be instrumental in the progression of
Abaxis as a leading point of care technology provider. I look
forward to working very closely with Brenton in the coming years."
About Abaxis Abaxis develops, manufactures and markets portable
blood analysis systems for use in any veterinary or human
patient-care setting to provide clinicians with rapid blood
constituent measurements. The system consists of a compact, 5.1
kilogram (11.2 pounds), portable analyzer and a series of
single-use plastic discs, called reagent discs that contain all the
chemicals required to perform a panel of up to 13 tests on
veterinary patients and 14 tests on human patients. The system can
be operated with minimal training and performs multiple routine
tests on whole blood, serum or plasma samples. The system provides
test results in less than 12 minutes with the precision and
accuracy equivalent to a clinical laboratory analyzer. Private
Securities Litigation Reform Act of 1995 This press release
includes statements that constitute "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995. Abaxis claims the protection of the safe-harbor for
forward-looking statements contained in the Reform Act. Specific
forward-looking statements contained in this press release include,
but are not limited to, risks and uncertainties related to the
market acceptance of the Company's products and the continuing
development of its products, risks associated with manufacturing
and distributing its products on a commercial scale, risks
associated with entering the human diagnostic market on a larger
scale, risks involved in carrying of inventory, risks from
unexpected problems or delays in the Company's manufacturing
facility, risks associated with the ability to attract and retain
competent sales personnel, general market conditions, competition,
risks and uncertainties related to its ability to raise capital in
order to fund its operations and other risks detailed from time to
time in Abaxis' periodic reports filed with the United States
Securities and Exchange Commission. Forward-looking statements
speak only as of the date the statement was made. Abaxis does not
undertake and specifically disclaims any obligation to update any
forward-looking statements. Contact: Clint Severson Lytham
Partners, LLC Chief Executive Officer Joe Dorame, Robert Blum and
Joe Diaz Abaxis, Inc. 602-889-9700 510-675-6500 DATASOURCE: Abaxis,
Inc. CONTACT: Clint Severson, Chief Executive Officer of Abaxis,
Inc., +1-510-675-6500; or Joe Dorame, Robert Blum and Joe Diaz, all
of Lytham Partners, LLC, +1-602-889-9700, for Abaxis, Inc.
Copyright